Jefferies Financial Group Inc. Acquires Shares of 103,900 LivaNova PLC (NASDAQ:LIVN)

Jefferies Financial Group Inc. purchased a new position in LivaNova PLC (NASDAQ:LIVN - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 103,900 shares of the company's stock, valued at approximately $4,812,000. Jefferies Financial Group Inc. owned 0.19% of LivaNova as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in LivaNova by 12.7% during the fourth quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company's stock valued at $108,823,000 after acquiring an additional 265,291 shares during the last quarter. Capital Research Global Investors lifted its position in LivaNova by 19.1% during the fourth quarter. Capital Research Global Investors now owns 1,612,818 shares of the company's stock valued at $74,690,000 after acquiring an additional 258,730 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in LivaNova by 8.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,310,990 shares of the company's stock valued at $60,710,000 after acquiring an additional 107,693 shares during the last quarter. Redmile Group LLC lifted its position in LivaNova by 19.3% during the fourth quarter. Redmile Group LLC now owns 1,043,539 shares of the company's stock valued at $48,326,000 after acquiring an additional 168,500 shares during the last quarter. Finally, Nuveen Asset Management LLC lifted its position in LivaNova by 0.6% during the fourth quarter. Nuveen Asset Management LLC now owns 823,412 shares of the company's stock valued at $38,132,000 after acquiring an additional 5,080 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. The Goldman Sachs Group cut their price target on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research note on Monday, March 3rd. Robert W. Baird upped their price target on shares of LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Wall Street Zen lowered shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 8th. Barclays cut their price target on shares of LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 8th. Finally, Wolfe Research upgraded shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price target on the stock in a research note on Tuesday, May 20th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $59.29.

LivaNova Stock Performance

Shares of NASDAQ:LIVN traded up $0.02 during midday trading on Friday, reaching $43.19. The company's stock had a trading volume of 596,572 shares, compared to its average volume of 655,499. The firm has a market capitalization of $2.35 billion, a PE ratio of 102.83 and a beta of 0.84. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $61.40. The stock has a fifty day moving average of $39.05 and a 200 day moving average of $44.28. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.